Sourvinos G, Spandidos D A
Medical School, University of Crete, Heraklion, Crete, 71409, Greece.
Biochem Biophys Res Commun. 1998 Apr 7;245(1):75-80. doi: 10.1006/bbrc.1998.8379.
Predisposition to breast cancer has been attributed to mutant BRCA1 alleles whereas no BRCA1 mutation has been described yet in sporadic breast tumours. As an initial characterization of the regulation and function of the BRCA1 gene in sporadic breast cancer, we have compared the expression of BRCA1 in thirty-five paired tumour specimens versus their corresponding adjacent normal tissue. We found two- to five-fold reduced BRCA1 expression levels in tumour specimens as compared to normal tissue. Decreased BRCA1 expression was significantly associated with loss of heterozygosity (LOH) at the BRCA1 region, as well as with negative estrogen receptor (ER) status. Our results offer an alternative explanation of how BRCA1 could play an important role in sporadic breast cancer, not via mutations in coding sequences but due to transcriptional disregulation. Decreased BRCA1 mRNA may be caused due to loss of gene copies, deletions of regulatory elements in the BRCA1 promoter or failure of transcriptional regulation by estrogen receptors. We also investigated possible relationships between BRCA1, p53, mdm-2 and p21(WAF1/CIP1) at the expression level. p53 expression was unaffected in almost all the specimens, mdm-2 was overexpressed in 18/35 specimens while 21/35 overexpressed p21. Samples exhibiting reduced BRCA1 levels simultaneously overexpressed both p21 and mdm-2, showing that BRCA1, at certain levels, even reduced up to 2.7-fold, is functional and sufficient to upregulate p21, when p53 activity is inhibited by its negative regulator, the mdm-2. On the contrary, specimens exhibiting more than 2.7-fold reduced BRCA1 levels, overexpressed p21 while mdm-2 expression was normal, allowing us to speculate that p21 transcriptional activation is due to p53 activity, in cases with dramatically decreased BRCA1 expression. Our findings provide evidence, indicating that BRCA1 might affect cell cycle regulation and loss of BRCA1 function due to decreased expression leads to cell cycle arrest, through p53 and p21 genes.
乳腺癌的易感性被认为与BRCA1等位基因突变有关,而散发性乳腺肿瘤中尚未发现BRCA1基因突变。作为对散发性乳腺癌中BRCA1基因调控和功能的初步表征,我们比较了35对肿瘤标本及其相应的相邻正常组织中BRCA1的表达。我们发现,与正常组织相比,肿瘤标本中BRCA1表达水平降低了2至5倍。BRCA1表达降低与BRCA1区域杂合性缺失(LOH)以及雌激素受体(ER)阴性状态显著相关。我们的结果为BRCA1如何在散发性乳腺癌中发挥重要作用提供了另一种解释,即不是通过编码序列中的突变,而是由于转录失调。BRCA1 mRNA降低可能是由于基因拷贝丢失、BRCA1启动子中调控元件的缺失或雌激素受体转录调控失败所致。我们还在表达水平上研究了BRCA1、p53、mdm-2和p21(WAF1/CIP1)之间的可能关系。几乎所有标本中p53表达均未受影响,18/35标本中mdm-2过表达,而21/35标本中p21过表达。BRCA1水平降低的样本同时过表达p21和mdm-2,表明在一定水平下,即使BRCA1水平降低至2.7倍,当p53活性被其负调节因子mdm-2抑制时,BRCA1仍具有功能且足以上调p21。相反,BRCA1水平降低超过2.7倍的标本中,p21过表达而mdm-2表达正常,这使我们推测在BRCA1表达显著降低的情况下,p21转录激活是由于p53活性所致。我们的研究结果提供了证据,表明BRCA1可能影响细胞周期调控,BRCA1表达降低导致其功能丧失,进而通过p53和p21基因导致细胞周期停滞。